Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data

Kazuya Sakai, Atsushi Hamamura, Yoshiko Yoshimura, Miyuki Abe, Yoshiyuki Ogawa, Kazuki Tanaka, Norimichi Hattori, Tazuko Tokugawa, Rie Kanai, Fumiyoshi Ikejiri, Masahiro Takeyama, Teruhisa Taoka, Naoki Fujita, Minoru Kanaya, Katsuyoshi Koh, Hiroshi Shiragami, Hidekazu Azumi, Kenki Saito, Masanori Matsumoto

Blood (2025) 145 (20): 2390–2395.

https://doi.org/10.1182/blood.2024027516

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Anticoagulant Function By the Addition of Heparinoid in Vitro in the Plasmas from Patients with Hemophilia and Von Willebrand Disease

Masahiro Takeyama, Tomoya Miyatake, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami

Blood (2023) 142 (Supplement 1): 5469.

https://doi.org/10.1182/blood-2023-174793

Published: 2023

Journal Articles

Contribution of the Residues 488-490 on the Factor (F)VIII A2 Domain and the Residue 2239 on the FVIII C2 Domain for the Interaction between FVIII and Protein S

Shoko Furukawa, Masahiro Takeyama, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2603.

https://doi.org/10.1182/blood-2023-174626

Published: 2023

Journal Articles

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

Kuniyoshi Mizumachi, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami

Blood (2022) 140 (Supplement 1): 8430–8431.

https://doi.org/10.1182/blood-2022-165714

Published: 2022

Journal Articles

Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients

Yuto Nakajima, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami

Blood (2021) 138 (Supplement 1): 2100.

https://doi.org/10.1182/blood-2021-146337

Published: 2021

Journal Articles

Contribution of Factor VIII A3 Domain Residues 1793-1795 to a Factor IXa-Interactive Site

Masahiro Takeyama, Keiji Nogami, MDPhD, Kana Sasai, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1173.

https://doi.org/10.1182/blood-2018-99-113260

Published: 2018

Journal Articles

Identification of a Factor X-Interactive Site on the Factor VIII A2 Domain

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Shoko Furukawa, MD, Midori Shima, MD PhD

Blood (2016) 128 (22): 3760.

https://doi.org/10.1182/blood.V128.22.3760.3760

Published: 2016

Journal Articles

Identification of a Protein S-Interactive Site on the Factor VIII C2 Domain

Furukawa Shoko, Masahiro Takeyama, MD PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2016) 128 (22): 3763.

https://doi.org/10.1182/blood.V128.22.3763.3763

Published: 2016

Journal Articles

Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)

Koji Yada, MDPhD, Keiji Nogami, MD PhD, Yasuaki Shida, MD PhD, Masahiro Takeyama, MD PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2015) 126 (23): 3503.

https://doi.org/10.1182/blood.V126.23.3503.3503

Published: 2015

Journal Articles

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 3565.

https://doi.org/10.1182/blood.V126.23.3565.3565

Published: 2015

Journal Articles

Factor VIII A2 Domain Contains a Binding Site for Factor X

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 4226.

https://doi.org/10.1182/blood.V124.21.4226.4226

Published: 2014

Journal Articles

Reduced Affinity To VWF Induced By a Novel Mutation At Pro1809Leu (factor VIII-Tenri) Is The Cause Of Mild Hemophilia A Developing Anti-Factor VIII Inhibitor

Koji Yada, MD, PhD, Keiji Nogami, MD, PhD, Masahiro Takeyama, MD, PhD, Hiroaki Minami, MD, Philip J. Fay, PhD, Midori Shima, MD, PhD

Blood (2013) 122 (21): 2343.

https://doi.org/10.1182/blood.V122.21.2343.2343

Published: 2013

Journal Articles

Mechanisms of Human Neutrophil Elastase-Catalyzed Inactivation of the Factor VIII(a).

Katsumi Nishiya, Keiji Nogami, Tomoko Matsumoto, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima

Blood (2009) 114 (22): 2125.

https://doi.org/10.1182/blood.V114.22.2125.2125

Published: 2009

Journal Articles

Effects of Anti-FVIII Inhibitors On Factor VIIa/Tissue Factor-Catalyzed Activation and Inactivation of Factor VIII.

Koji Yada, Keiji Nogami, Kenichi Ogiwara, Katsumi Nishiya, Masahiro Takeyama, Midori Shim

Blood (2009) 114 (22): 3169.

https://doi.org/10.1182/blood.V114.22.3169.3169

Published: 2009

Journal Articles

Interactions of Factor VIII with Tissue Factor Contributes to the Acceleration of Factor Xa Generation in the Initiation Phase of Blood Coagulation.

Kenichi Ogiwara, Keiji Nogami, Masahiro Okuda, Katsumi Nishiya, Masahiro Takeyama, Midori Shima

Blood (2009) 114 (22): 3177.

https://doi.org/10.1182/blood.V114.22.3177.3177

Published: 2009

Journal Articles

Determination for Coagulation Functions and Novel Inhibitory Mechanisms in Acquired Hemophilia A with Type 2 Inhibitors.

Tomoko Matsumoto, Keiji Nogami, Kenichi Ogiwara, Katsumi Nishiya, Masahiro Takeyama, Midori Shima

Blood (2009) 114 (22): 3483.

https://doi.org/10.1182/blood.V114.22.3483.3483

Published: 2009

Journal Articles

Identification of a Factor IXa-Interactive Site within the C2 Domain of Factor VIIIa and a Crucial Role of These Associations for the Process of Clot Formation

Tetsuhiro Soeda, Keiji Nogami, Kenichi Ogiwara, Masahiro Takeyama, Katsumi Nishiya, Midori Shima

Blood (2008) 112 (11): 1035.

https://doi.org/10.1182/blood.V112.11.1035.1035

Published: 2008

Journal Articles

Identification of a Protein S-Interactive Site on the Factor VIII A2 Domain.

Masahiro Takeyama, MD, Keiji Nogami, MD, PhD, Tetsuhiro Soeda, Akira Yoshioka, MD, PhD, Midori Shima, MD, PhD

Blood (2007) 110 (11): 2684.

https://doi.org/10.1182/blood.V110.11.2684.2684

Published: 2007

Journal Articles

Role of the Direct Interaction between Factor VIII C2 and Factor IXa Gla Domain in the Factor Xase Complex.

Tetsuhiro Soeda, Keiji Nogami, MD, PhD, Masahiro Takeyama, MD, Kenichi Ogiwara, MD, Kazuhiko Tomokiyo, PhD, Yoichi Sakata, MD, PhD, Akira Yoshioka, MD, PhD, Midori Shima, MD, PhD

Blood (2007) 110 (11): 2687.

https://doi.org/10.1182/blood.V110.11.2687.2687

Published: 2007

Journal Articles

Localization of Factor VIII Interactive Site within Plasmin/Plasminogen Which Is Responsible for Plasmin-Catalyzed Activation/Inactivation of Factor VIII.

Katsumi Nishiya, MD, Keiji Nogami, M.D., Kiyotaka Okada, M.D., Osamu Matsuo, M.D., Masahiro Takeyama, M.D., Kenichi Ogiwara, M.D., Ichiro Tanaka, M.D., Akira Yoshioka, M.D., Midori Shima, M.D.

Blood (2007) 110 (11): 1759.

https://doi.org/10.1182/blood.V110.11.1759.1759

Published: 2007

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data

Impact of Anticoagulant Function By the Addition of Heparinoid in Vitro in the Plasmas from Patients with Hemophilia and Von Willebrand Disease

Contribution of the Residues 488-490 on the Factor (F)VIII A2 Domain and the Residue 2239 on the FVIII C2 Domain for the Interaction between FVIII and Protein S

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients

Contribution of Factor VIII A3 Domain Residues 1793-1795 to a Factor IXa-Interactive Site

Identification of a Factor X-Interactive Site on the Factor VIII A2 Domain

Identification of a Protein S-Interactive Site on the Factor VIII C2 Domain

Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Factor VIII A2 Domain Contains a Binding Site for Factor X

Reduced Affinity To VWF Induced By a Novel Mutation At Pro1809Leu (factor VIII-Tenri) Is The Cause Of Mild Hemophilia A Developing Anti-Factor VIII Inhibitor

Mechanisms of Human Neutrophil Elastase-Catalyzed Inactivation of the Factor VIII(a).

Effects of Anti-FVIII Inhibitors On Factor VIIa/Tissue Factor-Catalyzed Activation and Inactivation of Factor VIII.

Interactions of Factor VIII with Tissue Factor Contributes to the Acceleration of Factor Xa Generation in the Initiation Phase of Blood Coagulation.

Determination for Coagulation Functions and Novel Inhibitory Mechanisms in Acquired Hemophilia A with Type 2 Inhibitors.

Identification of a Factor IXa-Interactive Site within the C2 Domain of Factor VIIIa and a Crucial Role of These Associations for the Process of Clot Formation

Identification of a Protein S-Interactive Site on the Factor VIII A2 Domain.

Role of the Direct Interaction between Factor VIII C2 and Factor IXa Gla Domain in the Factor Xase Complex.

Localization of Factor VIII Interactive Site within Plasmin/Plasminogen Which Is Responsible for Plasmin-Catalyzed Activation/Inactivation of Factor VIII.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only